Cargando…

Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma

SIMPLE SUMMARY: We tracked the cytotoxic potential of NK cells towards multiple myeloma cells in daratumumab-mediated antibody-dependent cellular cytotoxicity assays. These cytotoxicity levels could be directly correlated to the expression of the target antigen (CD38) and to the percentage of fratri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lejeune, Margaux, Duray, Elodie, Peipp, Matthias, Clémenceau, Béatrice, Baron, Frédéric, Beguin, Yves, Caers, Jo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234557/ https://www.ncbi.nlm.nih.gov/pubmed/34203012 http://dx.doi.org/10.3390/cancers13123072

Ejemplares similares

A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma
por: Duray, Elodie, et al.
Publicado: (2021)

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
por: Lejeune, Margaux, et al.
Publicado: (2020)

Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease
por: Muller, Joséphine, et al.
Publicado: (2018)

Integrative Analysis of Proteomics and Transcriptomics Reveals Endothelin Receptor B as Novel Single Target and Identifies New Combinatorial Targets for Multiple Myeloma
por: Lejeune, Margaux, et al.
Publicado: (2023)

Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in Osteoclasts
por: Muller, Joséphine, et al.
Publicado: (2019)

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
por: Nahi, Hareth, et al.
Publicado: (2019)

Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting
por: Viola, Domenico, et al.
Publicado: (2020)

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2023)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2020)

γδT cells are ADCC effectors in elite HIV controllers
por: Poonia, Bhawna, et al.
Publicado: (2010)

A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma
por: Decaup, Emilie, et al.
Publicado: (2019)

Natural Killer cells present in gut mucosa as potential ADCC effector cells
por: Sips, M, et al.
Publicado: (2012)

“Universal Flu Vaccine”: Can NK Cell-mediated ADCC Tip the Scales?
por: Hassane, Maya, et al.
Publicado: (2016)

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
por: Sanchez, Larysa, et al.
Publicado: (2016)

CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients
por: Frerichs, Kristine A., et al.
Publicado: (2019)

Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018)

CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy
por: Pape, Luca Julius, et al.
Publicado: (2022)

Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies
por: Wu, Hao-Tian, et al.
Publicado: (2022)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52(+) T-cell malignancies
por: Miljkovic, Milos D., et al.
Publicado: (2022)

Daratumumab in dialysis-dependent multiple myeloma
por: Jeyaraman, Preethi, et al.
Publicado: (2020)

Daratumumab efficacy in extramedullary orbital myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells
por: Dixon, Kate J., et al.
Publicado: (2021)

DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma
por: Choudhry, Priya, et al.
Publicado: (2019)

CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies
por: Perez de Acha, Olivia, et al.
Publicado: (2023)

Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC
por: Natsume, Akito, et al.
Publicado: (2009)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

FcγRIIIa receptor polymorphism influences NK cell mediated ADCC activity against HIV
por: Talathi, Sneha Pramod, et al.
Publicado: (2019)

Potential role of daratumumab in the treatment of multiple myeloma
por: Khagi, Yulian, et al.
Publicado: (2014)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab
por: Plesner, Torben
Publicado: (2021)

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab
por: García-Guerrero, Estefanía, et al.
Publicado: (2020)

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
por: Yarlagadda, Lakshmi, et al.
Publicado: (2021)

Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma
por: Binsfeld, Marilène, et al.
Publicado: (2016)

Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition
por: Di Modica, Martina, et al.
Publicado: (2015)

Establishment of a Murine Graft-versus-Myeloma Model Using Allogeneic Stem Cell Transplantation
por: Binsfeld, Marilène, et al.
Publicado: (2014)

Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model
por: Chen, Shanshan, et al.
Publicado: (2016)

Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC)
por: Khanna, Vidhi, et al.
Publicado: (2021)

Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
por: Eitler, Jiri, et al.
Publicado: (2021)

Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients
por: Reina-Ortiz, Chantal, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fdi0d5ibgrb14mb9q5a17q9eeb